File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Immediate argon laser peripheral iridoplasty as treatment for acute attack of primary angle-closure glaucoma: A preliminary study

TitleImmediate argon laser peripheral iridoplasty as treatment for acute attack of primary angle-closure glaucoma: A preliminary study
Authors
Issue Date1998
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ophtha
Citation
Ophthalmology, 1998, v. 105 n. 12, p. 2231-2236 How to Cite?
AbstractObjective: This study aimed to examine the intraocular pressure (IOP)- lowering effects and safety of immediate argon laser peripheral iridoplasty (ALPI) as a first-line treatment for acute primary angle-closure glaucoma (PACG). Design: A prospective cohort study. Participants: Ten consecutive patients with their first attack of PACG, with IOP of 40 mmHg or greater, were recruited into the study. Intervention: On presentation, each patient received topical pilocarpine (4%) and timolol (0.5%) and immediate ALPI as primary treatment. The IOPs at 15, 30, and 60 minutes after ALPI were documented by applanation tonometry. When the corneal edema had settled, laser peripheral iridotomy was performed as a definitive treatment. Main Outcome Measures: The IOP, corneal edema, and complications from ALPI were measured. Results: The mean IOP of this group of patients was reduced from 59.5 ± 10.4 mmHg to 28.7 ± 14.9 mmHg at 15 minutes, 21.7 ± 13.1 mmHg at 30 minutes, and 16.0 ± 9.4 mmHg at 60 minutes after ALPI. No complications from the laser procedure were encountered during the study period. In nine of the ten patients, the corneal edema cleared up 1 hour after ALPI. In the remaining patient, the cornea cleared up 2 hours after ALPI. Conclusion: From this preliminary study, immediate ALPI, without adjunctive systemic antiglaucoma treatment, appeared to be very effective in controlling the IOP and returning corneal clarity in acute PACG. Its safety also appeared reassuring and did not have the risks associated with conventional systemic therapies.
Persistent Identifierhttp://hdl.handle.net/10722/176353
ISSN
2015 Impact Factor: 6.75
2015 SCImago Journal Rankings: 4.745
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLam, DSCen_US
dc.contributor.authorLai, JSMen_US
dc.contributor.authorTham, CCYen_US
dc.date.accessioned2012-11-26T09:10:46Z-
dc.date.available2012-11-26T09:10:46Z-
dc.date.issued1998en_US
dc.identifier.citationOphthalmology, 1998, v. 105 n. 12, p. 2231-2236en_US
dc.identifier.issn0161-6420en_US
dc.identifier.urihttp://hdl.handle.net/10722/176353-
dc.description.abstractObjective: This study aimed to examine the intraocular pressure (IOP)- lowering effects and safety of immediate argon laser peripheral iridoplasty (ALPI) as a first-line treatment for acute primary angle-closure glaucoma (PACG). Design: A prospective cohort study. Participants: Ten consecutive patients with their first attack of PACG, with IOP of 40 mmHg or greater, were recruited into the study. Intervention: On presentation, each patient received topical pilocarpine (4%) and timolol (0.5%) and immediate ALPI as primary treatment. The IOPs at 15, 30, and 60 minutes after ALPI were documented by applanation tonometry. When the corneal edema had settled, laser peripheral iridotomy was performed as a definitive treatment. Main Outcome Measures: The IOP, corneal edema, and complications from ALPI were measured. Results: The mean IOP of this group of patients was reduced from 59.5 ± 10.4 mmHg to 28.7 ± 14.9 mmHg at 15 minutes, 21.7 ± 13.1 mmHg at 30 minutes, and 16.0 ± 9.4 mmHg at 60 minutes after ALPI. No complications from the laser procedure were encountered during the study period. In nine of the ten patients, the corneal edema cleared up 1 hour after ALPI. In the remaining patient, the cornea cleared up 2 hours after ALPI. Conclusion: From this preliminary study, immediate ALPI, without adjunctive systemic antiglaucoma treatment, appeared to be very effective in controlling the IOP and returning corneal clarity in acute PACG. Its safety also appeared reassuring and did not have the risks associated with conventional systemic therapies.en_US
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ophthaen_US
dc.relation.ispartofOphthalmologyen_US
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAdministration, Topicalen_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAnterior Eye Segment - Ultrasonographyen_US
dc.subject.meshCohort Studiesen_US
dc.subject.meshFemaleen_US
dc.subject.meshGlaucoma, Angle-Closure - Drug Therapy - Surgery - Ultrasonographyen_US
dc.subject.meshHumansen_US
dc.subject.meshIntraocular Pressureen_US
dc.subject.meshIris - Surgery - Ultrasonographyen_US
dc.subject.meshLaser Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOphthalmic Solutionsen_US
dc.subject.meshPilocarpine - Therapeutic Useen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshTimolol - Therapeutic Useen_US
dc.titleImmediate argon laser peripheral iridoplasty as treatment for acute attack of primary angle-closure glaucoma: A preliminary studyen_US
dc.typeArticleen_US
dc.identifier.emailLai, JSM: laism@hku.hken_US
dc.identifier.authorityLai, JSM=rp00295en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0161-6420(98)92237-0-
dc.identifier.pmid9855152-
dc.identifier.scopuseid_2-s2.0-0032471937en_US
dc.identifier.volume105en_US
dc.identifier.issue12en_US
dc.identifier.spage2231en_US
dc.identifier.epage2236en_US
dc.identifier.isiWOS:000077335500023-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLam, DSC=35500200200en_US
dc.identifier.scopusauthoridLai, JSM=7401939748en_US
dc.identifier.scopusauthoridTham, CCY=7006081241en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats